{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:55:38Z","timestamp":1788357338588,"version":"build-2803163510"},"reference-count":131,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023699","name":"Health Data Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma &amp; Immunology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.anai.2026.02.008","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:07:20Z","timestamp":1772294840000},"page":"520-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lessons learned regarding optimal use of biologics to achieve disease remission in severe asthma"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0729-5926","authenticated-orcid":false,"given":"Liam Michael","family":"Coyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela Jane","family":"McDowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam Gabriel","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.anai.2026.02.008_bib0001","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.anai.2024.12.004","article-title":"Epidemiology of asthma across the ages","volume":"134","author":"Miligkos","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.02.008_bib0002","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaci.2025.03.008","article-title":"Unraveling the heterogeneity of asthma: decoding subtypes of asthma","volume":"156","author":"Fuhlbrigge","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2026.02.008_bib0003","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Accessed December 2025. Available at: www.ginasthma.org"},{"key":"10.1016\/j.anai.2026.02.008_bib0004","doi-asserted-by":"crossref","first-page":"r1162","DOI":"10.1136\/bmj.r1162","article-title":"Asthma: diagnosis, monitoring, and chronic asthma management: summary of guidance from BTS\/NICE\/SIGN","volume":"390","author":"Fowler","year":"2025","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.anai.2026.02.008_bib0005","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.anai.2026.02.008_bib0006","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data from the international severe asthma registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.anai.2026.02.008_bib0007","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/thoraxjnl-2017-210531","article-title":"Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population","volume":"73","author":"Kerkhof","year":"2018","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.anai.2026.02.008_bib0008","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2026.02.008_bib0009","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12931-018-0742-y","article-title":"Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis","volume":"19","author":"Bloechliger","year":"2018","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.anai.2026.02.008_bib0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thoraxjnl-2015-207630","article-title":"Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry","volume":"71","author":"Sweeney","year":"2016","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.anai.2026.02.008_bib0011","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"issue":"9842","key":"10.1016\/j.anai.2026.02.008_bib0012","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.anai.2026.02.008_bib0013","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of Benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.anai.2026.02.008_bib0014","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1398-9995.2004.00770.x","article-title":"The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma","volume":"60","author":"Bousquet","year":"2005","journal-title":"Allergy"},{"issue":"26","key":"10.1016\/j.anai.2026.02.008_bib0015","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.anai.2026.02.008_bib0016","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.anai.2026.02.008_bib0017","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.anai.2026.02.008_bib0018","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of Benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.anai.2026.02.008_bib0019","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2026.02.008_bib0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.chest.2022.01.071","article-title":"Dupilumab reduces oral corticosteroid use in patients with corticosteroid-dependent severe asthma: an analysis of the Phase 3, open-label extension TRAVERSE trial","volume":"162","author":"Sher","year":"2022","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.anai.2026.02.008_bib0021","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-2600(25)00359-5","article-title":"Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial","volume":"14","author":"Jackson","year":"2026","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.anai.2026.02.008_bib0022","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"23","key":"10.1016\/j.anai.2026.02.008_bib0023","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber","year":"1948","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2026.02.008_bib0024","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM194801292380502","article-title":"The course of rheumatoid arthritis in patients receiving simple medical and orthopedic measures","volume":"238","author":"Short","year":"1948","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2026.02.008_bib0025","unstructured":"Merriam-Webster Medical Dictionary. Remission. Accessed December 2025. Available at: https:\/\/www.merriam-webster.com\/dictionary\/remission#medicalDictionary"},{"issue":"8","key":"10.1016\/j.anai.2026.02.008_bib0026","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/adc.52.8.613","article-title":"Natural history of childhood asthma. 20-year follow-up","volume":"52","author":"Blair","year":"1977","journal-title":"Arch Dis Child"},{"issue":"6","key":"10.1016\/j.anai.2026.02.008_bib0027","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jaci.2013.12.1033","article-title":"Outcomes of childhood asthma to the age of 50 years","volume":"133","author":"Tai","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2026.02.008_bib0028","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/thx.2010.146845","article-title":"Factors influencing asthma remission: a longitudinal study from childhood to middle age","volume":"66","author":"Burgess","year":"2011","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.anai.2026.02.008_bib0029","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/archpedi.161.12.1197","article-title":"Persistence and remission in childhood asthma: a population-based asthma birth cohort study","volume":"161","author":"To","year":"2007","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"10.1016\/j.anai.2026.02.008_bib0030","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2017.03.034","article-title":"Clinical predictors of remission and persistence of adult-onset asthma","volume":"141","author":"Westerhof","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2026.02.008_bib0031","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.rmed.2016.06.017","article-title":"A 12-year prognosis of adult-onset asthma: Seinajoki Adult Asthma Study","volume":"117","author":"Tuomisto","year":"2016","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.anai.2026.02.008_bib0032","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/ecco-jcc\/jjad086","article-title":"Defining biological remission in Crohn\u2019s disease: interest, challenges and future directions","volume":"17","author":"Pierre","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.anai.2026.02.008_bib0033","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/apt.13948","article-title":"Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus","volume":"45","author":"Vuitton","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.anai.2026.02.008_bib0034","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/ard.54.12.944","article-title":"Early rheumatoid arthritis: time to aim for remission?","volume":"54","author":"Emery","year":"1995","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.anai.2026.02.008_bib0035","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.anai.2026.02.008_bib0036","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","article-title":"Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with Benralizumab","volume":"39","author":"Menzies-Gow","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.anai.2026.02.008_bib0037","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/JAA.S391807","article-title":"Long-term efficacy and clinical remission after Benralizumab treatment in patients with severe eosinophilic asthma: A retrospective study","volume":"15","author":"Numata","year":"2022","journal-title":"J Asthma Allergy"},{"issue":"3","key":"10.1016\/j.anai.2026.02.008_bib0038","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.3390\/ijms24032455","article-title":"Severe asthma remissions induced by biologics targeting IL5\/IL5r: results from a multicenter real-life study","volume":"24","author":"Maglio","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.anai.2026.02.008_bib0039","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.anai.2026.02.008_bib0040","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.3390\/jcm12082900","article-title":"A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma","volume":"12","author":"Oishi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.anai.2026.02.008_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.anai.2026.02.008_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107348","article-title":"Severe asthma clinical remission after biologic treatment with anti-IL4\/IL13: a real-life experience","volume":"217","author":"Portacci","year":"2023","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.anai.2026.02.008_bib0043","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/j.jaip.2024.08.033","article-title":"Long-term clinical and sustained REMIssion in severe eosinophilic asthma treated with mepolizumab: the REMI-M study","volume":"12","author":"Crimi","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2026.02.008_bib0044","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.anai.2026.02.008_bib0045","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/cea.14544","article-title":"Overcoming barriers to remission in severe eosinophilic asthma: two-year real-world data with Benralizumab","volume":"54","author":"Jackson","year":"2024","journal-title":"Clin Exp Allergy"},{"issue":"10","key":"10.1016\/j.anai.2026.02.008_bib0046","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1080\/02770903.2024.2332351","article-title":"Real-world clinical remission of severe asthma with Benralizumab in Spanish adults with severe asthma","volume":"61","author":"Martinez-Moragon","year":"2024","journal-title":"J Asthma"},{"issue":"10","key":"10.1016\/j.anai.2026.02.008_bib0047","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/resp.14767","article-title":"Sustained remission induced by 2 years of treatment with Benralizumab in patients with severe eosinophilic asthma and nasal polyposis","volume":"29","author":"Pelaia","year":"2024","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.anai.2026.02.008_bib0048","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/jcm13010291","article-title":"Clinical remission in patients affected by severe eosinophilic asthma on dupilumab therapy: a long-term real-life study","volume":"13","author":"Quarato","year":"2024","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.anai.2026.02.008_bib0049","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2026.02.008_bib0050","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2024.10.009","article-title":"Dupilumab induces long-term on-treatment clinical remission in patients with Type 2 asthma","volume":"13","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2026.02.008_bib0051","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4168\/aair.2025.17.4.473","article-title":"Clinical remission outcome in Chinese patients with severe asthma with an eosinophilic phenotype receiving mepolizumab: a post-hoc analysis of a Phase 3, randomized, double-blind, placebo-controlled trial","volume":"17","author":"Chen","year":"2025","journal-title":"Allergy Asthma Immunol Res"},{"issue":"1","key":"10.1016\/j.anai.2026.02.008_bib0052","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000548349","article-title":"Benralizumab-induced asthma remission: impact of different tools and thresholds to define good asthma control","volume":"105","author":"Lommatzsch","year":"2026","journal-title":"Respiration"},{"issue":"2","key":"10.1016\/j.anai.2026.02.008_bib0053","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jaip.2025.10.011","article-title":"Long-term clinical remission on biologics: an analysis of real-world data from the UK severe asthma registry","volume":"14","author":"Redmond","year":"2026","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2026.02.008_bib0054","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.anai.2026.02.008_bib0055","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe asthma network Italy definition of clinical remission in severe asthma: a Delphi consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2026.02.008_bib0056","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.anai.2026.02.008_bib0057","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.arbres.2024.04.002","article-title":"Spanish consensus on remission in asthma (REMAS)","volume":"60","author":"Alvarez-Gutierrez","year":"2024","journal-title":"Arch Bronconeumol"},{"issue":"4","key":"10.1016\/j.anai.2026.02.008_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.opresp.2023.100277","article-title":"GEMA 5.3. Spanish guideline on the management of asthma","volume":"5","author":"Plaza Moral","year":"2023","journal-title":"Open Respir Arch"},{"issue":"8","key":"10.1016\/j.anai.2026.02.008_bib0059","first-page":"e3","article-title":"[Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023 - published by the German Respiratory Society (DGP) e. V.]","volume":"77","author":"Lommatzsch","year":"2023","journal-title":"Pneumologie"},{"issue":"3","key":"10.1016\/j.anai.2026.02.008_bib0060","first-page":"208","article-title":"[Guidelines for the prevention and management of bronchial asthma (2024 edition)]","volume":"48","year":"2025","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"3","key":"10.1016\/j.anai.2026.02.008_bib0061","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.resinv.2025.03.009","article-title":"Practical Guidelines for Asthma Management (PGAM): digest edition","volume":"63","author":"Tamaoki","year":"2025","journal-title":"Respir Investig"},{"issue":"1","key":"10.1016\/j.anai.2026.02.008_bib0062","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis","volume":"13","author":"Shackleford","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.anai.2026.02.008_bib0063","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1164\/rccm.202305-0808OC","article-title":"Association between T2-related comorbidities and effectiveness of biologics in severe asthma","volume":"209","author":"Wechsler","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2026.02.008_bib0064","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty asthma QUEST: Phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv Ther"},{"issue":"10056","key":"10.1016\/j.anai.2026.02.008_bib0065","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.anai.2026.02.008_bib0066","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2026.02.008_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107535","article-title":"Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma","volume":"224","author":"Papi","year":"2024","journal-title":"Respir Med"},{"issue":"11","key":"10.1016\/j.anai.2026.02.008_bib0068","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1007\/s12325-023-02659-y","article-title":"Effect of tezepelumab on lung function in patients with severe, uncontrolled asthma in the Phase 3 NAVIGATOR study","volume":"40","author":"Menzies-Gow","year":"2023","journal-title":"Adv Ther"},{"issue":"11","key":"10.1016\/j.anai.2026.02.008_bib0069","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202204-0671PP","article-title":"Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision","volume":"206","author":"Celli","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2026.02.008_bib0070","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. 2026 GOLD report and pocket guide. Accessed December 2025. Available at: https:\/\/goldcopd.org\/2026-gold-report-and-pocket-guide\/"},{"issue":"17","key":"10.1016\/j.anai.2026.02.008_bib0071","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJM199810223391703","article-title":"A 15-year follow-up study of ventilatory function in adults with asthma","volume":"339","author":"Lange","year":"1998","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.anai.2026.02.008_bib0072","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/thoraxjnl-2015-208138","article-title":"Identifying patients at risk for severe exacerbations of asthma: development and external validation of a multivariable prediction model","volume":"71","author":"Loymans","year":"2016","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.anai.2026.02.008_bib0073","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01619-2023","article-title":"Airway remodelling in asthma and the epithelium: on the edge of a new era","volume":"63","author":"Varricchi","year":"2024","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2026.02.008_bib0074","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jaci.2021.07.042","article-title":"Parenchymal destruction in asthma: fixed airflow obstruction and lung function trajectory","volume":"149","author":"Shimizu","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.02.008_bib0075","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jaip.2018.10.046","article-title":"Association between asthma and depression: a national cohort study","volume":"7","author":"Choi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2026.02.008_bib0076","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1378\/chest.130.4.1039","article-title":"What is worse for asthma control and quality of life: depressive disorders, anxiety disorders, or both?","volume":"130","author":"Lavoie","year":"2006","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.anai.2026.02.008_bib0077","first-page":"212","article-title":"Effects of depression and anxiety on asthma-related quality of life","volume":"84","author":"Lomper","year":"2016","journal-title":"Pneumonol Alergol Pol"},{"issue":"1","key":"10.1016\/j.anai.2026.02.008_bib0078","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12931-022-02266-5","article-title":"Associations of symptoms of anxiety and depression with health-status, asthma control, dyspnoea, dysfunction breathing and obesity in people with severe asthma","volume":"23","author":"Stubbs","year":"2022","journal-title":"Respir Res"},{"issue":"6","key":"10.1016\/j.anai.2026.02.008_bib0079","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3390\/jpm11060586","article-title":"Depression levels influence the rate of asthma exacerbations in females","volume":"11","author":"Anastasia","year":"2021","journal-title":"J Pers Med"},{"issue":"5","key":"10.1016\/j.anai.2026.02.008_bib0080","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.jaip.2018.01.010","article-title":"A randomized, double-blind, placebo-controlled trial of escitalopram in patients with asthma and major depressive disorder","volume":"6","author":"Brown","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2026.02.008_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107012","article-title":"Obesity and asthma: a focused review","volume":"204","author":"Tooba","year":"2022","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.anai.2026.02.008_bib0082","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCRESAHA.125.325676","article-title":"Obstructive sleep apnea and cardiometabolic disease: obesity, hypertension, and diabetes","volume":"137","author":"Tasali","year":"2025","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.anai.2026.02.008_bib0083","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jaip.2015.04.002","article-title":"Obstructive sleep apnea risk, asthma burden, and lower airway inflammation in adults in the Severe Asthma Research Program (SARP) II","volume":"3","author":"Teodorescu","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"15","key":"10.1016\/j.anai.2026.02.008_bib0084","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000041918","article-title":"Association of obstructive sleep apnea risk with allergic asthma: a systematic review and meta-analysis","volume":"104","author":"Liu","year":"2025","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.anai.2026.02.008_bib0085","article-title":"Interrelationship between obstructive sleep apnea syndrome and severe asthma: from endo-phenotype to clinical aspects","volume":"8","author":"Ragnoli","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.anai.2026.02.008_bib0086","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00160-2021","article-title":"Glucocorticoid toxicity reduction with mepolizumab using the glucocorticoid toxicity index","volume":"59","author":"McDowell","year":"2022","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.anai.2026.02.008_bib0087","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thorax-2021-217032","article-title":"Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study","volume":"78","author":"Soremekun","year":"2023","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.anai.2026.02.008_bib0088","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01497-2024","article-title":"Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma","volume":"65","author":"Soendergaard","year":"2025","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2026.02.008_bib0089","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard-2022-223413","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis. 2022 revision","volume":"82","author":"Studenic","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.anai.2026.02.008_bib0090","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.anai.2026.02.008_bib0091","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03393-2020","article-title":"Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation","volume":"58","author":"Busse","year":"2021","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.anai.2026.02.008_bib0092","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.jaci.2016.09.002","article-title":"Current application of exhaled nitric oxide in clinical practice","volume":"138","author":"Spahn","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2026.02.008_bib0093","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00413-2021","article-title":"Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma","volume":"58","author":"Kraft","year":"2021","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.anai.2026.02.008_bib0094","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2026.02.008_bib0095","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02536-2017","article-title":"Associations between blood eosinophils and decline in lung function among adults with and without asthma","volume":"51","author":"Hancox","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2026.02.008_bib0096","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/all.70031","article-title":"Predictors of response to biologics for severe asthma: a systematic review and meta-analysis","volume":"81","author":"Rattu","year":"2026","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.anai.2026.02.008_bib0097","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1164\/rccm.202310-1751LE","article-title":"Biomarkers associated with lung function decline and dupilumab response in patients with asthma","volume":"209","author":"Pavord","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.anai.2026.02.008_bib0098","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S2213-2600(21)00124-7","article-title":"Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the Liberty ASTHMA QUEST study: a post-hoc analysis","volume":"9","author":"Busse","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.anai.2026.02.008_bib0099","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S2213-2600(25)00037-2","article-title":"Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials","volume":"13","author":"Meulmeester","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.anai.2026.02.008_bib0100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","article-title":"Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide","volume":"77","author":"Couillard","year":"2022","journal-title":"Thorax"},{"issue":"10423","key":"10.1016\/j.anai.2026.02.008_bib0101","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.anai.2026.02.008_bib0102","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1016\/j.jaip.2025.08.027","article-title":"Observational analysis of biological remission as a treatment target for severe Asthma: UK severe asthma registry","volume":"13","author":"McDowell","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2026.02.008_bib0103","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/all.16590","article-title":"Clinical and biological remission with tezepelumab: the real-world response in severe uncontrolled asthma","volume":"80","author":"Gates","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2026.02.008_bib0104","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/JAA.S507008","article-title":"Combining dual biologics therapy for severe asthma: a series of ten cases","volume":"18","author":"Chen","year":"2025","journal-title":"J Asthma Allergy"},{"issue":"11","key":"10.1016\/j.anai.2026.02.008_bib0105","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3390\/jpm13111594","article-title":"Combination of biological therapy in severe asthma: where we are?","volume":"13","author":"Carriera","year":"2023","journal-title":"J Pers Med"},{"issue":"18","key":"10.1016\/j.anai.2026.02.008_bib0106","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N Engl J Med"},{"issue":"822","key":"10.1016\/j.anai.2026.02.008_bib0107","doi-asserted-by":"crossref","first-page":"eadu3759","DOI":"10.1126\/scitranslmed.adu3759","article-title":"The IL-33 and IL-4R\u03b1 blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma","volume":"17","author":"Asrat","year":"2025","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.anai.2026.02.008_bib0108","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01461-2024","article-title":"A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule","volume":"65","author":"Deiteren","year":"2025","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.anai.2026.02.008_bib0109","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1111\/all.14526","article-title":"Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation","volume":"75","author":"Hong","year":"2020","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2026.02.008_bib0110","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.02.008_bib0111","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2023.05.014","article-title":"Safety and Efficacy of dexpramipexole in Eosinophilic Asthma (EXHALE): a randomized controlled trial","volume":"152","author":"Siddiqui","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"24","key":"10.1016\/j.anai.2026.02.008_bib0112","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2026.02.008_bib0113","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cpt.70156","article-title":"Verekitug, a novel antibody antagonist to the TSLP receptor in adults with asthma: a 32-week randomized Phase 1b multiple ascending-dose trial","volume":"119","author":"Singh","year":"2026","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.anai.2026.02.008_bib0114","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2023.05.028","article-title":"Comprehensive characterization of difficult-to-treat asthma reveals near absence of T2-low status","volume":"11","author":"Rupani","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2026.02.008_bib0115","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.70035","article-title":"T2-low severe asthma clinical spectrum and impact: the Greek PHOLLOW cross-sectional study","volume":"15","author":"Porpodis","year":"2025","journal-title":"Clin Transl Allergy"},{"issue":"2","key":"10.1016\/j.anai.2026.02.008_bib0116","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jaip.2019.11.006","article-title":"T2-\u201clow\u201d asthma: overview and management strategies","volume":"8","author":"Fitzpatrick","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2026.02.008_bib0117","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.coi.2020.10.002","article-title":"Mechanisms of non-type 2 asthma","volume":"66","author":"Hudey","year":"2020","journal-title":"Curr Opin Immunol"},{"issue":"20","key":"10.1016\/j.anai.2026.02.008_bib0118","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.3390\/jcm14207137","article-title":"Neutrophilic asthma\u2014from mechanisms to new perspectives of therapy","volume":"14","author":"Iwaszko","year":"2025","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.anai.2026.02.008_bib0119","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41392-023-01502-8","article-title":"Inflammation and aging: signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.anai.2026.02.008_bib0120","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"suppl 2","key":"10.1016\/j.anai.2026.02.008_bib0121","first-page":"A74","article-title":"S104 Study of asthma exacerbations in patients on the IL-5 receptor blocker, Benralizumab \u2013 the BenRex study","volume":"79","author":"Logan","year":"2024","journal-title":"Thorax"},{"issue":"suppl 69","key":"10.1016\/j.anai.2026.02.008_bib0122","first-page":"PA365","article-title":"Characterizing exacerbations in severe asthma patients treated with tezepelumab","volume":"66","author":"Haris","year":"2025","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.anai.2026.02.008_bib0123","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaci.2025.05.031","article-title":"Analysis of airway inflammation demonstrates a mechanism for T2-biologic failure in asthma","volume":"156","author":"McDowell","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2026.02.008_bib0124","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jaip.2025.05.002","article-title":"Treatable traits as a pathway to remission in asthma","volume":"13","author":"Farinha","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2026.02.008_bib0125","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01509-2019","article-title":"Targeting treatable traits in severe asthma: a randomised controlled trial","volume":"55","author":"McDonald","year":"2020","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2026.02.008_bib0126","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.chest.2024.02.048","article-title":"Effect of azithromycin on asthma remission in adults with persistent uncontrolled asthma: a secondary analysis of a randomized, double-anonymized, placebo-controlled trial","volume":"166","author":"Thomas","year":"2024","journal-title":"Chest"},{"issue":"10095","key":"10.1016\/j.anai.2026.02.008_bib0127","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.anai.2026.02.008_bib0128","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1007\/s12325-025-03175-x","article-title":"The real-world impact of glucagon-like peptide 1 receptor agonists on asthma control in people with high-risk asthma and obesity","volume":"42","author":"Kaplan","year":"2025","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.anai.2026.02.008_bib0129","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"issue":"suppl 68","key":"10.1016\/j.anai.2026.02.008_bib0130","first-page":"OA2774","article-title":"Late Breaking Abstract - Efficacy of high- and low-dose rilzabrutinib from a phase 2 study","volume":"64","author":"Pavord","year":"2024","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.anai.2026.02.008_bib0131","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jaci.2021.01.037","article-title":"PrecISE: precision Medicine in Severe Asthma: an adaptive platform trial with biomarker ascertainment","volume":"147","author":"Israel","year":"2021","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of Allergy, Asthma &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626000694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626000694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T09:36:46Z","timestamp":1778060206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626000694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":131,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1081120626000694"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.02.008","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lessons learned regarding optimal use of biologics to achieve disease remission in severe asthma","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}